Navigation Links
Renova Therapeutics enters into agreement to receive stresscopin investigational new drug file from Janssen
Date:2/6/2017

SAN DIEGO, Calif., Feb. 6, 2017 /PRNewswire-USNewswire/ -- Renova™ Therapeutics, Inc., a biotechnology company developing gene therapy treatments for congestive heart failure and type 2 diabetes, announced today that it has entered into an agreement with Janssen Pharmaceuticals, Inc., whereby the investigational new drug (IND) file for stresscopin – a hormone involved in responses to physiological stress – will be transferred from Janssen, where it was previously under development. Renova Therapeutics plans to advance development of the stresscopin program as RT-400, a peptide infusion treatment for episodes of Acute Decompensated Heart Failure (ADHF).

In the United States, ADHF accounts for approximately half of all heart failure-related causes of hospitalization.1 From 2005 to 2010, the average estimated number of ADHF hospitalizations in the U.S. was 1.76 million.2 Annual mortality following an ADHF hospitalization is about 30%.3

"Obtaining this stresscopin program IND helps propel forward the development of our peptide infusion product candidate, RT-400," said Jack W. Reich, Ph.D., CEO and Co-founder of Renova Therapeutics. "With this data, we hope to see promising results as we initiate pivotal trials."

In addition, Renova Therapeutics holds an exclusive license to the stresscopin peptide from the nonprofit Research Development Foundation.

About Acute Decompensated Heart Failure
Acute Decompensated Heart Failure (ADHF) is a severe episode of acute respiratory distress in which a heart failure patient experiences a sudden or gradual onset of the signs of heart failure that requires either initiation or escalation of treatment to relieve symptoms and prevent death. ADHF is caused by severe fluid congestion of the body's organs, especially the lungs, due to the failing heart providing inadequate circulation.

Symptoms of ADHF can include difficulty breathing, waking up from sleep gasping for air, fatigue, swelling of the legs or feet, as well as chest pain and pressure. Most episodes require immediate emergency room visits or hospitalizations for treatment.

Current treatment options for ADHF primarily involve reducing the organ fluid levels with diuretics, delivered intravenously, and stabilizing heart function with vasodilators such as nitroglycerin. Additional treatments can include providing breathing support using a face mask or breathing tube, as well as an ultrafiltration process to remove fluids in people with ADHF associated with kidney failure.

About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The company's product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.

References
1 Chang PP, Chambless LE, Shahar E, et al. Incidence and Survival of Hospitalized Acute Decompensated Heart Failure in Four US Communities (from the Atherosclerosis Risk in Communities Study). The American journal of cardiology. 2014;113(3):504-510. doi:10.1016/j.amjcard.2013.10.032.
2 Agarwal SK, Wruck L, Quibrera M, et al. Temporal Trends in Hospitalization for Acute Decompensated Heart Failure in the United States, 1998–201. Am. J. Epidemiol. 2016; 183(5):462-470.
3 Dhingra A, Garg A, Kaur S, et al. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2014; 11(4):354–365.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/renova-therapeutics-enters-into-agreement-to-receive-stresscopin-investigational-new-drug-file-from-janssen-300402057.html


'/>"/>
SOURCE Renova Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Renova Therapeutics receives additional NIH grant to continue paracrine gene therapy research for congestive heart failure
2. Lonza and Renova Therapeutics Announce Manufacturing Agreement for Clinical Supply of RT-100 Gene Therapy
3. CEO and Co-Founder of Renova Therapeutics receives Entrepreneur of the Year award from Washington & Jefferson College
4. Renova Therapeutics appoints Richard Mac McCloskey to head companys clinical development efforts
5. Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments
6. Renova Therapeutics recruits seasoned expert to lead companys regulatory and quality efforts
7. ViveBio, LLC Enters Worldwide Exclusive Licensing Agreement with Renovar Inc. for Novel Urine Based Biomarker Technologies Covering Kidney Disease and Transplant Monitoring
8. Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round
9. Entest BioMedical Inc.s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche
10. The Biotech Market Grows as Demand for New Therapeutics Increases
11. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... Inc., (Nasdaq: NVAX ) today announced that data ... RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) ... the journal Vaccine (the data contained ... The Company previously announced top line results from ... F Vaccine with the goal of protecting infants from RSV ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists on ... the flipper will get rich in no time. But what about the buyers of ... for the buyer of a flipped house. An email recently sent to Gary Case ...
(Date:6/28/2017)... , ... June 28, 2017 , ... David B. Sosin, a founding partner ... took over the post of 2nd Vice President for the Illinois State Bar Association ... as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served in ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces ... of the award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer ... as a regional supplier of garden pea seed. As demand grew, the small company ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a Cincinnati ... to insurance assistance and financial planning services, is announcing the commencement of a ... the region facing financial crisis. , Matthew 25: Ministries (M25M) is an international ...
Breaking Medicine News(10 mins):